KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to 0.74.

  • Supernus Pharmaceuticals' Equity Ratio fell 143.48% to 0.74 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.74, marking a year-over-year decrease of 143.48%. This contributed to the annual value of 0.76 for FY2024, which is 496.76% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Equity Ratio is 0.74, which was down 143.48% from 0.77 recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Equity Ratio ranged from a high of 0.77 in Q2 2025 and a low of 0.48 during Q4 2021
  • Moreover, its 5-year median value for Equity Ratio was 0.71 (2023), whereas its average is 0.63.
  • In the last 5 years, Supernus Pharmaceuticals' Equity Ratio tumbled by 335.89% in 2022 and then soared by 4330.3% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Equity Ratio (Quarter) stood at 0.48 in 2021, then increased by 7.77% to 0.52 in 2022, then soared by 38.56% to 0.72 in 2023, then rose by 4.97% to 0.76 in 2024, then fell by 2.34% to 0.74 in 2025.
  • Its Equity Ratio stands at 0.74 for Q3 2025, versus 0.77 for Q2 2025 and 0.77 for Q1 2025.